Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $97,500.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $3.25, for a total transaction of $97,500.00. Following the completion of the transaction, the director directly owned 6,188,287 shares in the company, valued at approximately $20,111,932.75. This represents a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, July 7th, Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.96, for a total value of $158,400.00.
• On Tuesday, June 2nd, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.68, for a total value of $110,400.00.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock opened at $3.22 on Friday. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of -3.10 and a beta of 1.03. The company has a current ratio of 5.03, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.77 and a 12 month high of $7.18. The stock’s 50 day moving average is $3.32 and its 200-day moving average is $3.45.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The firm had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same period in the previous year, the business posted ($0.41) earnings per share. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -0.9 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on RXRX shares. Wall Street Zen downgraded Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Morgan Stanley lifted their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $8.10.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 18.6% during the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock worth $192,998,000 after purchasing an additional 7,407,606 shares in the last quarter. ARK Investment Management LLC raised its stake in Recursion Pharmaceuticals by 11.2% in the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after purchasing an additional 3,771,357 shares in the last quarter. State Street Corp raised its stake in Recursion Pharmaceuticals by 38.7% in the fourth quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after purchasing an additional 7,064,963 shares in the last quarter. Geode Capital Management LLC lifted its position in Recursion Pharmaceuticals by 13.6% during the fourth quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company’s stock worth $44,731,000 after purchasing an additional 1,310,695 shares during the period. Finally, Norges Bank bought a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $23,473,000. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.